Abstract: There is described a pharmaceutical composition suitable for application to the skin and comprising, as active ingredient, a compound of formula I, ##STR1## in which R.sub.1 represents hydrogen, hydroxy or --NR.sub.5 R.sub.6, in which R.sub.5 and R.sub.6, which may be the same or different, each represent hydrogen or alkyl C 1 to 6,an adjacent pair of R.sub.2, R.sub.3 and R.sub.4 form a --(CH.sub.2).sub.4 -- chain, and the remaining substituent R.sub.2 or R.sub.4 represents alkyl C 1 to 9,E represents a 5-(IH)tetrazolyl- or a -COOH group, andX represents oxygen or a group --NR.sub.7 -- in which R.sub.7 may be hydrogen or alkyl C 1 to 6, or a pharmaceutically acceptable derivative thereof.

Abstract: There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carb oxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention).There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Abstract: There is described a pharmaceutical composition suitable for application to the skin and comprising, as active ingredient, a compound of formula I, ##STR1## in which R.sub.1 represents hydrogen, hydroxy or --NR.sub.5 R.sub.6, in which R.sub.5 and R.sub.6, which may be the same or different, each represent hydrogen or alkyl C 1 to 6,An adjacent pair of R.sub.2, R.sub.3 and R.sub.4 form a --(CH.sub.2).sub.4 -- chain, and the remaining substituent R.sub.2 or R.sub.4 represents alkyl C 1 to 9,E represents a 5-(IH)tetrazolyl- or a --COOH group, andX represents oxygen or a group --NR.sub.7 -- in which R.sub.7 may be hydrogen or alkyl C 1 to 6, or a pharmaceutically acceptable derivative thereof.

Abstract: There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho-[2,3-b]pyran-2-car boxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention).There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Abstract: There is described a method of treatment of certain skin conditions, which method comprises per os administration of a compound of the formula I ##STR1## or a therapeutically acceptable salt, ester or amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, (as active ingredient), to a patient having such a condition.